Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)

Templeton, Arnoud J; Dutoit Vallotton, Valérie; Cathomas, Richard; Rothermundt, Christian; Bärtschi, Daniela; Dröge, Cornelia; Gautschi, Oliver; Borner, Markus; Fechter, Eva; Stenner, Frank; Winterhalder, Ralph; Müller, Beat; Schiess, Ralph; Wild, Peter J; Rüschoff, Jan H; Thalmann, George; Dietrich, Pierre-Yves; Aebersold, Ruedi; Klingbiel, Dirk; Gillessen, Silke

doi:10.1016/j.eururo.2013.03.040

Scientific article

English

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)

Published inEuropean urology, vol. 64, no. 1, p. 150-158

Publication date2013

Abstract

The phosphatase and tensin homolog (PTEN) tumor suppressor gene is deregulated in many advanced prostate cancers, leading to activation of the phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway and thus increased cell survival.

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Immunothérapie des cancers (42)

Citation (ISO format)

TEMPLETON, Arnoud J et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). In: European urology, 2013, vol. 64, n° 1, p. 150–158. doi: 10.1016/j.eururo.2013.03.040

Article (Published version)

Identifiers

PID : unige:33771
DOI : 10.1016/j.eururo.2013.03.040
PMID : 23582881

Journal ISSN0302-2838

614views

0downloads

Creation12/12/2013 22:40:00

First validation12/12/2013 22:40:00

Update14/03/2023 20:54:35

Status update14/03/2023 20:54:34

Last indexation30/10/2024 16:05:02

Archive ouverte UNIGE

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)

The phosphatase and tensin homolog (PTEN) tumor suppressor gene is deregulated in many advanced prostate cancers, leading to activation of the phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway and thus increased cell survival.

Technical informations